Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Malaria, Vivax | 10 | 2025 | 36 | 4.890 |
Why?
|
| Plasmodium vivax | 11 | 2025 | 34 | 3.860 |
Why?
|
| Toxoplasma | 5 | 2025 | 32 | 2.080 |
Why?
|
| Toxoplasmosis, Ocular | 3 | 2025 | 7 | 1.750 |
Why?
|
| CD4-Positive T-Lymphocytes | 8 | 2025 | 620 | 1.740 |
Why?
|
| Interferon-gamma | 5 | 2025 | 551 | 1.740 |
Why?
|
| Monocytes | 8 | 2021 | 345 | 1.700 |
Why?
|
| Cytokines | 11 | 2023 | 912 | 1.480 |
Why?
|
| Toxoplasmosis | 3 | 2025 | 20 | 1.230 |
Why?
|
| Adaptive Immunity | 3 | 2025 | 98 | 1.220 |
Why?
|
| Malaria | 5 | 2023 | 101 | 1.140 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2025 | 147 | 1.110 |
Why?
|
| Reticulocytes | 3 | 2021 | 12 | 1.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 11 | 2022 | 648 | 1.040 |
Why?
|
| Asymptomatic Infections | 2 | 2025 | 18 | 1.000 |
Why?
|
| Mitochondria | 2 | 2021 | 343 | 0.950 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2024 | 6 | 0.910 |
Why?
|
| Chagas Disease | 3 | 2019 | 34 | 0.820 |
Why?
|
| Inflammation Mediators | 3 | 2020 | 170 | 0.810 |
Why?
|
| Immunity | 2 | 2019 | 101 | 0.770 |
Why?
|
| Antibodies, Protozoan | 2 | 2019 | 48 | 0.720 |
Why?
|
| B-Lymphocytes | 4 | 2024 | 550 | 0.690 |
Why?
|
| Host-Parasite Interactions | 2 | 2019 | 55 | 0.670 |
Why?
|
| Inflammation | 5 | 2023 | 1099 | 0.670 |
Why?
|
| Young Adult | 13 | 2025 | 4267 | 0.660 |
Why?
|
| Adult | 21 | 2025 | 15669 | 0.660 |
Why?
|
| T-Lymphocytes | 3 | 2020 | 986 | 0.640 |
Why?
|
| Receptors, CCR5 | 1 | 2019 | 56 | 0.630 |
Why?
|
| Lymphocyte Activation | 8 | 2024 | 743 | 0.600 |
Why?
|
| Immunologic Memory | 2 | 2019 | 281 | 0.600 |
Why?
|
| Cardiomyopathies | 1 | 2019 | 119 | 0.560 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2017 | 109 | 0.560 |
Why?
|
| Middle Aged | 17 | 2025 | 16317 | 0.560 |
Why?
|
| Cell Movement | 1 | 2019 | 428 | 0.550 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 207 | 0.520 |
Why?
|
| Male | 24 | 2025 | 27738 | 0.510 |
Why?
|
| Receptors, IgG | 2 | 2021 | 35 | 0.510 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2021 | 143 | 0.490 |
Why?
|
| Female | 25 | 2025 | 30704 | 0.490 |
Why?
|
| Humans | 38 | 2025 | 59356 | 0.480 |
Why?
|
| T-Lymphocyte Subsets | 6 | 2022 | 244 | 0.470 |
Why?
|
| Disease Progression | 1 | 2019 | 1122 | 0.460 |
Why?
|
| Immune Tolerance | 1 | 2015 | 172 | 0.460 |
Why?
|
| Trypanosoma cruzi | 4 | 2024 | 49 | 0.440 |
Why?
|
| Dendritic Cells | 5 | 2019 | 515 | 0.440 |
Why?
|
| Erythrocytes | 1 | 2014 | 146 | 0.440 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2015 | 281 | 0.430 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 241 | 0.410 |
Why?
|
| Interleukin-10 | 5 | 2023 | 149 | 0.410 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 2 | 2022 | 15 | 0.380 |
Why?
|
| Tuberculosis | 3 | 2022 | 270 | 0.380 |
Why?
|
| Adolescent | 9 | 2021 | 5824 | 0.380 |
Why?
|
| Immunophenotyping | 5 | 2021 | 184 | 0.350 |
Why?
|
| Neutrophils | 3 | 2021 | 363 | 0.340 |
Why?
|
| Leishmaniasis, Cutaneous | 2 | 2008 | 15 | 0.330 |
Why?
|
| Plasmodium berghei | 2 | 2019 | 21 | 0.320 |
Why?
|
| Chronic Disease | 2 | 2024 | 716 | 0.320 |
Why?
|
| Toxoplasmosis, Congenital | 2 | 2021 | 3 | 0.290 |
Why?
|
| Dengue | 2 | 2020 | 92 | 0.290 |
Why?
|
| Th1 Cells | 4 | 2025 | 174 | 0.290 |
Why?
|
| Reactive Oxygen Species | 2 | 2021 | 205 | 0.280 |
Why?
|
| Aged | 8 | 2024 | 13416 | 0.270 |
Why?
|
| Parasitemia | 2 | 2025 | 35 | 0.260 |
Why?
|
| Cell Proliferation | 3 | 2019 | 941 | 0.250 |
Why?
|
| Acute Disease | 2 | 2020 | 660 | 0.250 |
Why?
|
| Immunity, Innate | 3 | 2021 | 774 | 0.250 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2023 | 238 | 0.240 |
Why?
|
| Antiprotozoal Agents | 2 | 2021 | 8 | 0.230 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 3 | 2012 | 70 | 0.200 |
Why?
|
| Toll-Like Receptors | 2 | 2019 | 426 | 0.200 |
Why?
|
| Chemokines | 2 | 2021 | 93 | 0.200 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2012 | 119 | 0.200 |
Why?
|
| Anopheles | 1 | 2021 | 17 | 0.190 |
Why?
|
| Glycolysis | 1 | 2021 | 54 | 0.180 |
Why?
|
| Disease Susceptibility | 2 | 2019 | 157 | 0.180 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2018 | 70 | 0.180 |
Why?
|
| Extracellular Traps | 1 | 2021 | 41 | 0.180 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2021 | 16 | 0.180 |
Why?
|
| Phagosomes | 1 | 2021 | 54 | 0.180 |
Why?
|
| Flow Cytometry | 5 | 2017 | 644 | 0.180 |
Why?
|
| Malaria Vaccines | 2 | 2019 | 27 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2021 | 138 | 0.180 |
Why?
|
| Lymphocytes | 1 | 2021 | 190 | 0.180 |
Why?
|
| Mice | 11 | 2022 | 10289 | 0.180 |
Why?
|
| Gene Expression | 2 | 2021 | 809 | 0.170 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 1479 | 0.170 |
Why?
|
| Superoxide Dismutase | 1 | 2021 | 213 | 0.170 |
Why?
|
| Yellow Fever | 1 | 2019 | 3 | 0.170 |
Why?
|
| Yellow fever virus | 1 | 2019 | 4 | 0.170 |
Why?
|
| Yellow Fever Vaccine | 1 | 2019 | 3 | 0.170 |
Why?
|
| Th2 Cells | 2 | 2018 | 99 | 0.170 |
Why?
|
| Adenosine Triphosphate | 1 | 2021 | 289 | 0.160 |
Why?
|
| Malaria, Cerebral | 1 | 2019 | 23 | 0.160 |
Why?
|
| Antigens, Protozoan | 1 | 2019 | 43 | 0.160 |
Why?
|
| Animals | 14 | 2022 | 19648 | 0.160 |
Why?
|
| Receptors, CCR4 | 1 | 2018 | 4 | 0.160 |
Why?
|
| Child | 4 | 2020 | 4174 | 0.150 |
Why?
|
| Leishmania major | 1 | 2018 | 8 | 0.150 |
Why?
|
| Amphotericin B | 1 | 2018 | 21 | 0.150 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2018 | 12 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 8 | 2018 | 3230 | 0.140 |
Why?
|
| Squalene | 1 | 2017 | 1 | 0.140 |
Why?
|
| Interferon Type I | 2 | 2017 | 169 | 0.140 |
Why?
|
| alpha-Tocopherol | 1 | 2017 | 18 | 0.140 |
Why?
|
| Trigeminal Ganglion | 1 | 2017 | 4 | 0.140 |
Why?
|
| Leishmania | 2 | 2008 | 12 | 0.140 |
Why?
|
| Polysorbates | 1 | 2017 | 39 | 0.140 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2017 | 219 | 0.130 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2017 | 86 | 0.130 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 171 | 0.130 |
Why?
|
| Herpesvirus 1, Human | 1 | 2017 | 78 | 0.130 |
Why?
|
| Influenza Vaccines | 1 | 2017 | 90 | 0.130 |
Why?
|
| Interleukin-8 | 1 | 2016 | 87 | 0.130 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2017 | 202 | 0.130 |
Why?
|
| Phagocytosis | 2 | 2014 | 260 | 0.130 |
Why?
|
| Adjuvants, Immunologic | 1 | 2017 | 224 | 0.130 |
Why?
|
| Granulocytes | 1 | 2015 | 69 | 0.130 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 218 | 0.120 |
Why?
|
| Mice, Knockout | 6 | 2018 | 1993 | 0.120 |
Why?
|
| HIV Infections | 1 | 2022 | 913 | 0.120 |
Why?
|
| CTLA-4 Antigen | 1 | 2014 | 70 | 0.120 |
Why?
|
| Interleukin-6 | 1 | 2016 | 310 | 0.120 |
Why?
|
| Melanoma, Experimental | 1 | 2014 | 40 | 0.120 |
Why?
|
| Cancer Vaccines | 1 | 2014 | 46 | 0.120 |
Why?
|
| Brazil | 3 | 2021 | 88 | 0.110 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 133 | 0.110 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2021 | 391 | 0.110 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 1550 | 0.110 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2012 | 26 | 0.100 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2012 | 33 | 0.100 |
Why?
|
| Immunotherapy | 1 | 2014 | 230 | 0.100 |
Why?
|
| Interleukin-17 | 1 | 2012 | 88 | 0.100 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 844 | 0.090 |
Why?
|
| Cells, Cultured | 4 | 2021 | 2093 | 0.090 |
Why?
|
| Macrophages | 1 | 2017 | 1015 | 0.090 |
Why?
|
| Receptors, CXCR3 | 2 | 2022 | 35 | 0.090 |
Why?
|
| Primary Cell Culture | 2 | 2021 | 75 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 439 | 0.090 |
Why?
|
| Cell Differentiation | 3 | 2021 | 1301 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 178 | 0.080 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 292 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2014 | 850 | 0.080 |
Why?
|
| CD8 Antigens | 1 | 2008 | 53 | 0.080 |
Why?
|
| Healthy Volunteers | 2 | 2020 | 66 | 0.080 |
Why?
|
| CD4 Antigens | 1 | 2008 | 148 | 0.070 |
Why?
|
| Dengue Virus | 2 | 2020 | 95 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 2050 | 0.070 |
Why?
|
| Plasmodium chabaudi | 1 | 2007 | 23 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 2373 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2020 | 588 | 0.070 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2007 | 202 | 0.070 |
Why?
|
| Infant | 2 | 2021 | 1486 | 0.060 |
Why?
|
| Leishmaniasis | 1 | 2005 | 10 | 0.060 |
Why?
|
| Leukocytes | 1 | 2005 | 97 | 0.060 |
Why?
|
| Norepinephrine | 1 | 2005 | 98 | 0.060 |
Why?
|
| Dopamine | 1 | 2005 | 102 | 0.060 |
Why?
|
| Biomarkers | 2 | 2021 | 1306 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2005 | 201 | 0.060 |
Why?
|
| Phenotype | 2 | 2021 | 1137 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2005 | 179 | 0.060 |
Why?
|
| Nucleocapsid | 1 | 2022 | 12 | 0.050 |
Why?
|
| Nucleocapsid Proteins | 1 | 2022 | 35 | 0.050 |
Why?
|
| Drug Combinations | 2 | 2017 | 147 | 0.050 |
Why?
|
| CD4-CD8 Ratio | 1 | 2021 | 16 | 0.050 |
Why?
|
| Sulfadiazine | 1 | 2021 | 2 | 0.050 |
Why?
|
| Pyrimethamine | 1 | 2021 | 7 | 0.050 |
Why?
|
| Blood | 1 | 2021 | 29 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 2374 | 0.050 |
Why?
|
| Lymphopenia | 1 | 2021 | 35 | 0.050 |
Why?
|
| Time | 1 | 2021 | 26 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 95 | 0.050 |
Why?
|
| GPI-Linked Proteins | 1 | 2021 | 39 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 55 | 0.050 |
Why?
|
| Interleukins | 1 | 2021 | 80 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2019 | 1782 | 0.050 |
Why?
|
| Seasons | 1 | 2021 | 123 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2021 | 85 | 0.050 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2021 | 117 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2021 | 343 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2021 | 153 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 84 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2019 | 40 | 0.040 |
Why?
|
| RNA Helicases | 1 | 2020 | 88 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2020 | 130 | 0.040 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2020 | 93 | 0.040 |
Why?
|
| Spleen | 2 | 2013 | 480 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2018 | 68 | 0.040 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2018 | 105 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2021 | 2900 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2018 | 61 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 677 | 0.040 |
Why?
|
| Transcriptome | 1 | 2021 | 339 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2021 | 1283 | 0.030 |
Why?
|
| Granzymes | 1 | 2017 | 18 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1051 | 0.030 |
Why?
|
| Vaccination | 1 | 2019 | 334 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 868 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 258 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 220 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2016 | 259 | 0.030 |
Why?
|
| Acute-Phase Reaction | 1 | 2013 | 18 | 0.030 |
Why?
|
| Macrophages, Peritoneal | 1 | 2013 | 73 | 0.030 |
Why?
|
| HLA-DR Antigens | 1 | 2012 | 27 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2013 | 147 | 0.030 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2012 | 5 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2012 | 57 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 689 | 0.020 |
Why?
|
| Superoxides | 1 | 2012 | 69 | 0.020 |
Why?
|
| Haplotypes | 1 | 2012 | 115 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2012 | 48 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2013 | 243 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2012 | 258 | 0.020 |
Why?
|
| Alleles | 1 | 2012 | 411 | 0.020 |
Why?
|
| Genotype | 1 | 2012 | 617 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 627 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 6071 | 0.020 |
Why?
|
| Arginase | 1 | 2008 | 6 | 0.020 |
Why?
|
| Forecasting | 1 | 2008 | 219 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2017 | 5284 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2005 | 97 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 446 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 527 | 0.010 |
Why?
|